Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.

Jenny Nguy Sarah A Hitchen Nick Si Rui LanGirish DwivediRobert LarbalestierBu B Yeap P Gerry Fegan

Published in: Internal medicine journal (2022)

Prescribing of non-statin LDL-C-lowering therapies remains low in patients with ASCVD. Underprescribing of ezetimibe and suboptimal lipid testing rates are barriers to accessing subsidised PCSK9i therapy using current Australian eligibility criteria.

Keyphrases

low density lipoprotein
primary care
coronary artery disease
coronary artery
adverse drug
cardiovascular disease
fatty acid
stem cells
type diabetes
left ventricular
aortic valve
smoking cessation